U Herz1, A Braun, R Rückert, H Renz. 1. Department of Clinical Chemistry and Biochemistry, Virchow-Klinikum of the Humboldt-University Berlin, Germany.
Abstract
BACKGROUND: Bronchial asthma is characterized by a TH2 type immune response, chronic inflammation of the airways and increased airway responsiveness. The relationship between IgE- and inflammatory-dependent mechanisms that contribute to bronchial asthma are not well defined. OBJECTIVE: The purpose of this study was to compare and analyse the immune pathways that resulted in development of allergen-induced and/or inflammatory dependent increased airways responsiveness. RESULTS: BALB/c and C57BL/6 mice responded to OVA-sensitization with elevated allergen-specific IgE/IgG1 serum antibody-titres and the development of cutaneous immediate-type hypersensitivity reactions. Increased airway responsiveness was observed following airway allergen challenges. However, the inflammatory component of the lung differed between the strains. In OVA-sensitized BALB/c mice a marked increase in lymphocytes, eosinophils and neutrophils in BAL fluids was parallelled with elevated production of IL-4, IL-5 and TNFalpha in the lung. In contrast in OVA-sensitized C57BL/6 mice, the inflammatory immune response in the lung was much weaker. We postulate that two pathways can regulate the induction of increased airway responsiveness. One depends on the presence of allergen-specific IgE/IgG1 and allergen, and a second is mediated by allergen-independent inflammation of the lung. To test this hypothesis, BALB/c mice were treated nasally with low doses of bacterial superantigen (SEB) as a prototypical inducer of airway inflammation, following which influx of lymphocytes, eosinophils and neutrophils into the airways was parallelled by development of increased airway-responsiveness in the absence of allergen-specific IgE/IgG1 antibodies and allergen. CONCLUSIONS: These results indicate that increased airway responsiveness is associated with different immunological phenotypes in BALB/c and C57BL/6 mice.
BACKGROUND:Bronchial asthma is characterized by a TH2 type immune response, chronic inflammation of the airways and increased airway responsiveness. The relationship between IgE- and inflammatory-dependent mechanisms that contribute to bronchial asthma are not well defined. OBJECTIVE: The purpose of this study was to compare and analyse the immune pathways that resulted in development of allergen-induced and/or inflammatory dependent increased airways responsiveness. RESULTS: BALB/c and C57BL/6 mice responded to OVA-sensitization with elevated allergen-specific IgE/IgG1 serum antibody-titres and the development of cutaneous immediate-type hypersensitivity reactions. Increased airway responsiveness was observed following airway allergen challenges. However, the inflammatory component of the lung differed between the strains. In OVA-sensitized BALB/c mice a marked increase in lymphocytes, eosinophils and neutrophils in BAL fluids was parallelled with elevated production of IL-4, IL-5 and TNFalpha in the lung. In contrast in OVA-sensitized C57BL/6 mice, the inflammatory immune response in the lung was much weaker. We postulate that two pathways can regulate the induction of increased airway responsiveness. One depends on the presence of allergen-specific IgE/IgG1 and allergen, and a second is mediated by allergen-independent inflammation of the lung. To test this hypothesis, BALB/c mice were treated nasally with low doses of bacterial superantigen (SEB) as a prototypical inducer of airway inflammation, following which influx of lymphocytes, eosinophils and neutrophils into the airways was parallelled by development of increased airway-responsiveness in the absence of allergen-specific IgE/IgG1 antibodies and allergen. CONCLUSIONS: These results indicate that increased airway responsiveness is associated with different immunological phenotypes in BALB/c and C57BL/6 mice.
Authors: Sebastian Kerzel; Tobias Rogosch; Julia Wagner; Kathrin Preisser; Ali-Önder Yildirim; Heinz Fehrenbach; Holger Garn; Rolf F Maier; Harry W Schroeder; Michael Zemlin Journal: Int Arch Allergy Immunol Date: 2011-06-29 Impact factor: 2.749
Authors: S Kerzel; J Wagner; T Rogosch; A-O Yildirim; L Sikula; H Fehrenbach; H Garn; R F Maier; H W Schroeder; M Zemlin Journal: Clin Exp Allergy Date: 2009-02-03 Impact factor: 5.018
Authors: A M Dittrich; H-A Meyer; M Krokowski; D Quarcoo; B Ahrens; S M Kube; M Witzenrath; R S Esworthy; F-F Chu; E Hamelmann Journal: Eur Respir J Date: 2009-11-06 Impact factor: 16.671
Authors: Armin Braun; Marek Lommatzsch; Ulrich Neuhaus-Steinmetz; David Quarcoo; Thomas Glaab; Gerard P McGregor; Axel Fischer; Harald Renz Journal: Br J Pharmacol Date: 2004-01-12 Impact factor: 8.739
Authors: M L Conrad; A O Yildirim; S S Sonar; A Kiliç; S Sudowe; M Lunow; R Teich; H Renz; H Garn Journal: Clin Exp Allergy Date: 2009-05-03 Impact factor: 5.018